Monte Rosa Therapeutics Announced MRT-8102 Is Expected To Be Developed For Inflammatory Diseases Driven By Interleukin-1β And The NLRP3 Inflammasome. This Is The First Development Candidate To Be Declared From The Company's NEK7 Development Program
Monte Rosa Therapeutics 宣佈，MRT-8102 有望開發用於白介素-1β 和 NLRP3 炎症體驅動的炎性疾病。這是該公司NEK7開發計劃中宣佈的第一個開發候選人